New Cell Therapy Product, BlueCellule™, Enters Development Stage

NEW YORK - Sept. 15, 2015 - PRLog -- BHI Therapeutic Sciences, LLC has recently started development of a promising new clinical cell therapy line called BlueCellule™.

"BlueCellule™ is a compound that could revolutionalize the forefront of medical science," said Dr. Brian Mehling - founder of BHI Therapeutic Sciences, LLC.

"This is the beginning of an extensive process that will transform the way we think of cell therapies," said Doreen Santora - COO of BHI Therapeutic Sciences, LLC. "Stem cell therapy has become the next frontier of medicine, proving to upset even the most basic assumptions of how we treat disease and traumatic injury."

Not only does Blue Horizon Therapeutic Sciences, LLC provide quality care and service for medical treatments globally, it advances research in stem cell therapies and provides resources needed to assist children and adults who are medically underserved.

For more information about BlueCellule™ or BHI Therapeutic Sciences, LLC, please visit the BHI Therapeutic Sciences, LLC website at the following web address: www.bhisciences.com